Redeye maintain our view of Alzecure and Alzheimer’s candidate ACD856, a part of the company's Neurorestore platform, following today’s announcement that the first person has been dosed in the MAD (“Multiple Ascending Dose”) phase I study. We are encouraged that the project is progressing and that the timeline is kept (expected readout H1 2022) and look forward to the results.